Willingness to receive Human Papilloma Virus (HPV) vaccination in patients after surgical treatment for Cervical Intraepithelial Neoplasia

Rationale: The Human Papilloma Virus (HPV) is essential in the carcinogenesis of cervical cancer. Among other countries, the Netherlands have implemented a nationwide vaccination programme to reduce HPV infection in girls. However, multiple parents and eligible participants refused the HPV vaccination due to possible safety concerns. Recent studies have examined the tertiary prevention properties of the HPV vaccination. Women who underwent cervical surgery due to HPV-induced precancerous lesions (Cervical Intraepithelial Neoplasia), were vaccinated. They concluded that HPV vaccination reduces subsequent HPV-related diseases. To implement tertiary prevention of cervical cancer, the willingness to vaccinate in the target group should be examined to prevent possible rejection of the HPV vaccination implementation.
Objective: To explore the willingness to receive HPV vaccination in women who were treated with cervical surgery for CIN. In addition, the level of knowledge of HPV in patients with CIN will be examined
Study design: Prospective questionnaire study
Study population: Women who underwent cervical surgery in the Catharina Hospital due to CIN II-III or High-Grade Squamous Intraepithelial Lesions (HSIL) will be included.
Intervention: A 13-item questionnaire will be used.
Main study parameters: Willingness to vaccinate, with or without financial contribution.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The questionnaire will only take approximately 5 minutes of the participants time. Therefore, there is no significant burden or risk for the participants, neither is there a possible benefit.

Women will be willing to receive HPV vaccination to reduce the risk of recurrent HPV-related disease

After surgical treatment for Cervical Intraepithelial Neoplasia

13-item questionnaire